StockData
Cadrenal Therapeutics, Inc. logo

Cadrenal Therapeutics, Inc. (CVKD) company profile

CVKDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 9/30
$1.88+0.48 (+34.29%)

Close on Nov 17, 2026Market cap $6.71MP/E –Yield 877.66%

About Cadrenal Therapeutics

Pharmaceutical Preparations, SIC 2834

Cadrenal Therapeutics, Inc. is a biopharmaceutical company that develops therapies for life-threatening immune and thrombotic conditions. Its lead drug candidate, CAD-1005, is a selective 12-lipoxygenase inhibitor evaluated for the treatment and prevention of heparin-induced thrombocytopenia. The company's pipeline also includes tecarfarin, an oral vitamin K antagonist intended for patients with end-stage kidney disease and atrial fibrillation or left ventricular assist devices, and frunexian, an intravenous Factor XIa inhibitor for acute hospital care. The company focuses on patient populations with complex anticoagulation requirements and high thrombotic risks.

The company is headquartered in Ponte Vedra, Florida, and is incorporated in Delaware. Operating primarily in the United States biopharmaceutical sector, its research scale includes clinical development programs that span Phase 1 through Phase 3 preparations, with candidate studies evaluating cohorts ranging from small patient groups to more than one thousand clinical subjects.

Summary of the business section of Cadrenal Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Cadrenal Therapeutics, Inc.
Headquarters
Ponte Vedra, FL
Address
822 A1a North, Suite 306 32082
Phone
(904) 300-0701
Employees
5, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
WithumSmith+Brown, PC, East Brunswick, New Jersey

Stock & identifiers

Ticker
CVKD
Exchange
Nasdaq
IPO date
Jan 23, 2023
Shares outstanding
4M, Aug 13, 2026
Public float
$24.87M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Stock splits
1-for-15 reverse, Aug 20, 2024
SEC CIK
1937993
CUSIP
127636207
ISIN
US1276362076
FIGI
BBG019STRT20
Share class FIGI
BBG019STRT39
EIN
88-0860746

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Quang X. PhamChairman and CEO, Director298,589
Jeffrey Scott ColeChief Operating Officer–
Matthew K. SzotChief Financial Officer0
James J. Ferguson IIIChief Medical Officer–
Glynn WilsonDirector50,000
Lee Scott GoldenDirector1,667
John Raymond MurphyDirector614,792
Steven ZelenkofskeDirector40,000
Robert LisickiDirector–

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsOtherTotalvs. prior year
Quang X. Pham
Chief Executive Officer
$751.28K$296.75K$847.67K$14.00K$1.91M+56%
Matthew Szot
Former Chief Financial Officer
$459.72K$181.59K$652.05K$13.67K$1.31M+51%
James J. Ferguson
Former Chief Medical Officer
$457.41K$136.35K$778.92K$23.13K$1.40M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jan 23, 2023
Offer price
$5.00
Securities offered
1,400,000
Gross proceeds
$7.00M
Exchange
Nasdaq
First trading day
Jan 20, 2023
First-day close
$4.12-17.6%
Lock-up ends (est.)
Jul 19, 2023

“We are offering 1,400,000 shares of our common stock, par value $0.001 per share (“common stock”), at the initial public offering price of $5.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of March 27, 2025, we had five employees, all of which are full-time, and engage approximately thirty-five consultants and contractors.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?